<DOC>
	<DOC>NCT01318694</DOC>
	<brief_summary>This study will assess the safety and efficacy of alisporivir (ALV; DEB025) triple therapy [i.e., when added to peginterferon alfa-2a (PEG) and ribavirin (RBV)] to optimize treatment in treatment-naïve participants with hepatitis C virus (HCV) genotype 1 (GT1)</brief_summary>
	<brief_title>Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Inclusion criteria: Chronic HCV infection HCV genotype 1 No previous treatment for hepatitis C infection Serum HCV RNA level ≥ 1000 IU/ml assessed by quantitative polymerase chain reaction or equivalent at screening, no upper limit Liver evaluation prior to baseline: liver biopsy within 3 years or Fibroscan within 6 months Exclusion criteria: HCV genotype different from genotype 1 or coinfection with other HCV genotype Coinfection with Hepatitis B or HIV Any other cause of relevant liver disease other than HCV Presence or history of hepatic decompensation Alanine aminotransferase (ALT) ≥ 10 times upper limit of normal (ULN), more than 1 episode of elevated bilirubin (&gt; ULN) in past 6 months Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Cyclophilin inhibitor</keyword>
</DOC>